Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1CNS 1

Conditions

Wilms Tumor 1Sarcoma, Synovial 1Rhabdomyosarcoma 1Pleuropulmonary blastoma 1Neurofibrosarcoma 1Neuroblastoma 1

Interventions

fludarabine 2Ifosfamide 2Filgrastim 2Doxorubicin 2Cyclophosphamide 2tazemetostat 1pembrolizumab 1lorvotuzumab mertansine 1ixabepilone 1cixutumumab 1Radiotherapy 1Radiation 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Immunotherapy, Adoptive 1Immunotherapy 1Imatinib Mesylate 1Drug Therapy 1Chemotherapy, Adjuvant 1CLR1404 1Biological Therapy 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Synovial × lorvotuzumab mertansine × Genitourinary × Clear all
NCT02452554 2022-01-13

Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma

Children's Oncology Group

Phase 2 Completed
62 enrolled 15 charts
CNSGenitourinarySarcoma

Pleuropulmonary blastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Synovial, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡